These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38681979)

  • 1. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
    Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
    Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
    Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
    Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study.
    Ando K; Fujiya M; Ueno N; Ito T; Maemoto A; Nasuno M; Tanaka H; Sakurai K; Katsurada T; Orii F; Ashida T; Motoya S; Kazama T; Yokoyama Y; Hirayama D; Nakase H
    Crohns Colitis 360; 2024 Apr; 6(2):otae024. PubMed ID: 38711858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study.
    Nomura K; Shibuya T; Odakura R; Haraikawa M; Ishino H; Orikasa M; Omori M; Koma M; Ito K; Maruyama T; Nomura O; Ishikawa D; Hojo M; Nagahara A
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
    Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
    J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States.
    Hong SJ; Krugliak Cleveland N; Akiyama S; Zullow S; Yi Y; Shaffer SR; Malter LB; Axelrad JE; Chang S; Hudesman DP; Rubin DT
    Crohns Colitis 360; 2021 Jan; 3(1):otab002. PubMed ID: 36777067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis.
    Uchida G; Nakamura M; Yamamura T; Maeda K; Sawada T; Ishikawa E; Furukawa K; Iida T; Mizutani Y; Yamao K; Ishikawa T; Ishizu Y; Honda T; Ishigami M; Kawashima H
    Inflamm Intest Dis; 2023 Oct; 8(2):60-68. PubMed ID: 37901340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
    Tursi A; Mocci G; Scaldaferri F; Napolitano D; Maresca R; Pugliese D; Semprucci G; Savarino E; Cuomo A; Donnarumma L; Bodini G; Pasta A; Maconi G; Cataletti G; Pranzo G; Rodinò S; Sebkova L; Costa F; Ferronato A; Gaiani F; Marzo M; Luppino I; Fabiano G; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Grossi L; Serio M; Scarcelli A; Lorenzetti R; Allegretta L; Chiri S; Grasso G; Antonelli E; Bassotti G; Spagnuolo R; Luzza F; Fanigliulo L; Rocco G; Sacchi C; Zampaletta C; Rocchi C; Bolognini L; Bendia E; Bianco MA; Capone P; Meucci C; Colucci R; Tonti P; Neve V; Della Valle N; Felice C; Pica R; Cocco A; Forti G; Onidi FM; Usai Satta P; Checchin D; Gravina AG; Pellegrino R; Picchio M; Papa A
    Expert Opin Biol Ther; 2024; 24(1-2):101-109. PubMed ID: 38250818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
    Gros B; Ross H; Nwabueze M; Constantine-Cooke N; Derikx LAAP; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Plevris N
    Therap Adv Gastroenterol; 2024; 17():17562848241258372. PubMed ID: 39086990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
    Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
    Thunberg J; Björkqvist O; Hedin CRH; Forss A; Söderman C; Bergemalm D; ; Olén O; Hjortswang H; Strid H; Ludvigsson JF; Eriksson C; Halfvarson J
    United European Gastroenterol J; 2022 Sep; 10(7):631-639. PubMed ID: 35834389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis - a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial.
    Talar-Wojnarowska R; Fabisiak A; Zatorski H; Płoszka K; Błaziak K; Fendler W; Rydzewska G; Małecka-Wojciesko E; Eder P
    Front Med (Lausanne); 2024; 11():1458998. PubMed ID: 39364021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan.
    Omori M; Shibuya T; Ishino H; Fukuo Y; Odakura R; Koma M; Maruyama T; Ito K; Haraikawa M; Nomura K; Yano S; Nomura O; Ishikawa D; Hojo M; Osada T; Nagahara A
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy.
    Chiappetta MF; Viola A; Mastronardi M; Turchini L; Carparelli S; Orlando A; Biscaglia G; Miranda A; Guida L; Costantino G; Scaldaferri F; Bossa F; Renna S; Cappello M; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Expert Opin Biol Ther; 2021 Nov; 21(11):1483-1489. PubMed ID: 34521307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.
    Eder P; Kłopocka M; Cichoż-Lach H; Talar-Wojnarowska R; Kopertowska-Majchrzak M; Michalak A; Filip R; Waszak K; Stawczyk-Eder K; Janiak M; Skrobot K; Liebert A; Zatorski H; Solarska-Półchłopek A; Krogulecki M; Pękała A; Poniewierka E; Smoła I; Kaczka A; Wojciechowski K; Drygała S; Zagórowicz E
    Therap Adv Gastroenterol; 2023; 16():17562848231151295. PubMed ID: 36818601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).
    Sabhan H; Bello F; Muhsen S; Borin A; Johansson F; Höög C; Forsberg O; Wennerström C; Lördal M; Almer S; Söderman C
    Eur J Gastroenterol Hepatol; 2024 Dec; 36(12):1419-1425. PubMed ID: 39324963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.
    Huang K; Liu J; Xia W; Tian C; Yao L; Cao Q; Chen H
    Front Pharmacol; 2023; 14():1188751. PubMed ID: 37214457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.